"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

Nantes University Hospital450 enrolled

Overview

The goal of this clinical trial is to determine the safety (phase II), then efficacy (phase III) of baricitinib plus standard of care (SOC) as compared to SOC alone for the treatment of hospital-acquired pneumonia in patients with a pro-inflammatory profile.

For both groups : At inclusion visit : * Verification of inclusion and non-inclusion criteria * Patient information and signature of consent form * Pregnancy test (urine ou blood) * Randomization * Clinical evaluation (cardiac frequency, saturation, tracheal secretions, PaO2/FiO2 ratio, body temperature, mechanical ventilation support) * Collection of respiratory fluid and blood for biobank * Liver function test (AST, ALT, bilirubin), blood white cells count and EKG * Treatment compliance * Concomitant medications (antimicrobial therapy and steriods) * Survival and EQ-5D-5L At visit 1 to visit 10 ( Day1- day10) * Clinical evaluation (cardiac frequency, saturation, tracheal secretions, PaO2/FiO2 ratio, body temperature, mechanical ventilation support) * Study drug administration (daily) * Collection of respiratory fluid and blood for biobank (day 3 and day 7) * Liver function test (AST, ALT, bilirubin), blood white cells count and EKG (Liver, day 3 and day 7) * Treatment compliance * Adverse event * Concomitant medications (antimicrobial therapy and steriods) At visit 11(Day 10-12 test-of-cure) : * Clinical evaluation (cardiac frequency, saturation, tracheal secretions, PaO2/FiO2 ratio, body temperature, mechanical ventilation support) * Collection of respiratory fluid and blood for biobank * Collection of the respiratory fluid for bacterial cure * Liver function test (AST, ALT, bilirubin), blood white cells count and EKG * Adverse event * Concomitant medications (antimicrobial therapy and steriods) At visit 12 : * Adverse event * Survival and EQ-5D-5L At visit 13 (month 3) and visit 14 (month 6) : * Query in NHI Database (SNDS) for consumption of Health resources (pharmaceuticals, consultations...) * Survival and EQ-5D-5L * Health -related quality of the life (SF-36), anxiety/depression (HADS), subjective well-being (SWLS) * Interview with a researcher in pshychology (20 patients and their relatives - only in France)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

450

Conditions

Hospital-acquired Pneumonia

Interventions

Baricitinib 4 MGDRUG

Reference drug

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ventilators-associated pneumonia (VAP) or hospital -acquired pneumonia requiring invasive ventilation (V-HAP) * Diagnosis of HAP according to European guidelines : association of two clinical criteria (body temperature \> 38°c and purulent pulmonary secretions), the appearance of a new infiltrate or change in an existing infiltrate on chest radography, and respiratory sample (AET, BAL, mini-BAL or blind BAL) collected for bacteriological diagnosis (results can be pending at inclusion). The diagnosis of HAP can have been made outside of ICU * VAP : patients should have received machenical ventilation via an endotracheal or nasotracheal tube for the least 48h at the time of HAP diagnosis. V-HAP : patients should have been hospitalized for the least 48 hours before the onset of the first signs or symptoms and required invasive mechanical ventilation during HAP treatment * Biological systemic inflammatory response defined according to the on-site standard of acre (CPR \> 125 mg/L and/or PCT \> 2µg/L and/or ferritin blood level \> 650 ng/mL * Receiving antimicrobal therapy for the current episode of HAP pneumonia for less than 72 hours * Informed consent from legal representative or emergency procedure (when possible according to national regulation). If it's impossible to obtain patient consent before the inclusion (comatose patients), patient consent for the study continuation will be obtained as soon as deemed possible * Person insured under a helth insurance scheme Exclusion Criteria: * Pregnant women (serum or urine test), breastfeeding woment * Patient under legal protection (inc. under guardianship or trusteesheep) * Hypersensitivity to baricitinib * Uncontrolled herpes zoster, viral hepatitis, infection with human immunodeficiency virus, fungal infections or tuberculosis * Severe hepatic insufficiency (child-Pugh B or C) * Acute or chronic renal insufficiency (modification of diet in renal disease (MDRD) creatinine clearance \< 30 ml/min/1.73 m²) * Persistent anemia (haemoglobin \< 8 g/L), lymphopenia (absolute lymphocyte \< 500 cells/mm3) * Immunosuppression (hematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion or anti-graft rejection drug) * Recent (\<90 days) trhomboembolic event (venous trhombosis, pulmonary embolism, myocardial infarction, and/or stroke) * Participation to an interventional drug study within 1 month prior to the inclusion

Locations (29)

St-Luc Clinics

Brussels, Belgium

Outcomes

Primary Outcomes

Determine the safety (phase II), of baricitinib plus standard of care (SOC) as compared to (SOC) alone for the treatment of hospital-acquired pneumonia in patients with a pro-inflammatory profile

Using a hierarchic procedure. We will test the baricitinib superiority on the clinical cure rate at the test-of-cure visit realized 10-12 days after randomization or at the ICU discharge. If the superiority criterion is met at the test-of-cure visit, we will test the baricitinib superiority on the rate of all-cause mortality on Day 28

Time frame: Day 28

Determine the efficacy (phase III) of baricitinib plus standard of care (SOC) as compared to (SOC) alone for the treatment of hospital-acquired pneumonia in patients with a pro-inflammatory profile

Time frame: Day 28

Secondary Outcomes

To demonstrate the efficacy of baricitinib on pneumonia-associated morbidity reduction

In case of a non-significant difference in the rate of clinical cure, the co-primary outcome will be presented as a secondary outcome.

Time frame: Day 28

To demonstrate the efficacy of baricitinib on pneumonia-associated mortality reduction

In case of a non-significant difference in the rate of clinical cure, the co-primary outcome will be presented as a secondary outcome.

Time frame: Day 28

To demonstrate the efficacy of baricitinib on pneumonia-associated morbidity

All-cause morbidity at Month 3 and Month 6

Time frame: Month 3 and Month 6

Central Contacts

Astrid GARREAU

CONTACT

+33 (0) 2 53 48 28 40 astrid.garreau@chu-nantes.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.